AgeGroup is proud to sponsor Longevitech TLV 2023, taking place in Tel Aviv, Israel, on the 13th and 14th of February. Ahead of the event, we’ve interviewed many of the individuals who will be participating in Longevitech TLV 2023 to learn about them and their businesses. In this feature, we meet Yaacov Goldenhersh from LiST Funding.
Hi Yaacov, thank you for speaking with us. Please introduce yourself and your business to our readers…
I’m Yaacov Goldenhersh, co-founder and CEO of LiST Funding.
LiST Funding is a life science research business that utilises large scale medical data in order to develop machine learning predictions for underwriting longevity.
That sounds really interesting – what specific ageing issue is LiST Funding looking to deal with?
LiST is addressing longevity markets where the likelihood of life-changing medical events or life expectancy assessments have an impact on their course of action, financials, risk factors and decision making. For instance, the way annuities or long-term care is priced is dependent on the state of health of the applicant; or the question if an individual should undergo a medical procedure or pursue long-term care services can be dependent on life expectancy predictions. Additionally, for seniors with assets that can be liquidated in secondary markets, such as their life insurance or home equity, medical underwriting is crucial.
Got it. So how does LiST Funding go about doing this?
LiST brought together a team of experts combining medical doctors, actuaries, medical underwriters, and data scientists in order to develop a market disrupting prediction tool for medical life changing events. LiST utilises advanced machine learning models in order to predict life expectancy, by analysing hundreds of data points within the medical history of the patient, in an all-inclusive, holistic manner. Upon providing the system with an individual’s medical history, our underwriting tool can produce a medically underwritten longevity prediction within minutes, enabling our customers to achieve real-time, data-driven, underwriting.
Thank you for sharing that. Can you tell us a little more about the background of LiST Funding and your product?
LiST is backed by venture capital and revenue generated by its customers.
The founding team of LiST has experience with various longevity linked asset classes and found a common thread within these groups- a key risk factor for the seniors and market players who provide liquidity is medical underwriting. Medical underwriting solutions for seniors are generally carried out by utilizing generic legacy systems without giving enough attention to details, which can lead to inconsistent and inaccurate predictions. As such, we decided to establish LiST and create a personalised data-driven solution, analysing the entire medical history and comorbidity factors impacting on the patient and producing precise and consistent results at scale.
LiST is a commercial solution, currently in use, in the longevity linked asset management space. LiST provides medical underwriting and risk assessment to our clients in these areas and is working on developing a full SaaS product in order to serve the greater longevity market.
We are excited about the opportunity to assist the broader medical research community by utilizing the data and prediction capabilities we are continuously developing.
Thanks again for taking the time to speak with us. We look forward to seeing you at Longevitech!
You can learn more about LiST Funding at https://listfunding.com/.
Longevitech TLV 2023 takes place across 13th – 14th February.
